DYNAMICS OF APOE BINDING TO LIPOPROTEINS AND RECEPTORS

APOE 与脂蛋白和受体结合的动力学

基本信息

  • 批准号:
    3366035
  • 负责人:
  • 金额:
    $ 16.19万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1993
  • 资助国家:
    美国
  • 起止时间:
    1993-04-01 至 1998-03-31
  • 项目状态:
    已结题

项目摘要

ApoE is found in a number of animal species and although it is synthesized by various cell types, most plasma apoE is produced by the liver. In the circulation, apoE participates in lipid transport by mediating lipoprotein binding to the B/E receptor. A key factor in plasma lipid transport is the capacity of apoE to exchange between lipoprotein surfaces; however, not all apoE is capable of transfer, and not all lipoprotein-associated apoE is receptor active. The factors which govern apoE transfer between lipoproteins and receptor binding capacity are unclear. Two lines of evidence demonstrate that apoE secreted by the liver may be modified by fatty acid acylation. Whether this acylation is related to the functional state of plasma apoE is not known. Recently it has been suggested that a portion of the apoE synthesized by hepatic cells is not secreted, but remains within the cell where it may participate in intracellular lipid transport. The signal which determines whether apoE is secreted or remains in the cell is undefined, however, in other systems, targeting of proteins to specific cellular sites is accomplished by fatty acid acylation. The possibility that fatty acid acylation of apoE might affect its functional capacities in the plasma and/or its trafficking within the cell is intriguing. The goal of this project is to understand the factors which affect apoE transferability and receptor binding capacity and control targeting of apoE to intra- and extracellular pools. This goal will be accomplished through four aims designed to examine the existence and origins of different physical states of apoE and to probe their influence on apoE functional capacity. First, the physical and physiological state of the apoE component of nascent VLDL (isolated from the liver) will be examined by determining the susceptibility of apoE to thrombin cleavage, the capacity of apoE to transfer off of VLDL, and the capacity of apoE to mediate binding of nascent VLDL to the B/E receptor. The second aim is to examine fatty acid acylation of apoE and determine the appearance of apoE acylation in differing cell types and animal species, the localization of acyl-apoE in a specific lipoprotein class, the fatty acid specificity and site(s) of acylation, and the physical and physiological consequences of apoE acylation. The third aim is to examine cellular aspects of apoE acylation and determine the role of acylation in targeting of apoE to intra- and extracellular pools, the temporal relationship of apoE acylation to protein synthesis and post-translational modifications, and factors which influence apoE acylation. Finally, site-directed mutagenesis will be used to modify the acylation site(s) of apoE, and the cDNA will be transfected into hepatocytes to examine the effect of the modifications on targeting of apoE to intra- and extracellular pools, association of apoE with specific lipoproteins, and apoE transferability and thrombin sensitivity.
Apoe在许多动物物种中都发现,尽管它是 由各种细胞类型合成,大多数血浆APOE由 肝。 在循环中,Apoe通过 介导脂蛋白与B/E受体结合。 一个关键因素 等离子体脂质传输是APOE之间交换的能力 脂蛋白表面;但是,并非所有ApoE都能转移,并且 并非所有与脂蛋白相关的APOE都是活性的。 因素 控制脂蛋白与受体结合之间的APOE转移 容量尚不清楚。 两条证据表明APOE 由肝脏分泌可以通过脂肪酸酰化来改变。 无论 该酰基化与等离子体APOE的功能状态无关 已知。最近有人提出了APOE的一部分 由肝细胞合成的不是分泌,而是保留在细胞内 它可能参与细胞内脂质转运。 信号 哪个确定APOE是分泌还是保留在单元格中 但是,在其他系统中未定义,将蛋白质靶向特定 细胞位点是通过脂肪酸酰化来完成的。 可能性 APOE的脂肪酸酰化可能会影响其功能能力 在血浆和/或其在细胞内的运输中,很有趣。 这 该项目的目标是了解影响APOE的因素 可转移性和受体结合能力和控制靶向 APOE到细胞内和细胞外池。 这个目标将实现 通过四个目的旨在检查 APOE的不同物理状态并探究其对APOE的影响 功能能力。 首先,的身体和生理状态 将检查新生VLDL的APOE组件(从肝脏隔离) 通过确定APOE对凝血酶裂解的敏感性, APOE转移VLDL的能力,以及ApoE的能力 新生VLDL与B/E受体的介导结合。 第二个目标是 检查APOE的脂肪酸酰化并确定 不同细胞类型和动物种类中的apoe酰基化, 在特定的脂蛋白类别(脂肪酸)中定位酰基-APOE 酰化的特异性和部位,以及物理和生理 APOE酰化的后果。 第三个目的是检查细胞 APOE酰化的各个方面并确定酰化在 靶向APOE到细胞内和细胞外池,时间为时间 Apoe酰化与蛋白质合成的关系 翻译后修改以及影响APOE的因素 酰化。 最后,将使用位置定向的诱变来修改 APOE的酰化位点,将cDNA转染到 肝细胞检查修饰对靶向的影响 APOE与细胞内和细胞外池,APOE与特定的关系 脂蛋白,APOE的转移性和凝血酶敏感性。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Martha P. Mims其他文献

Paraneoplastic Nephrotic Syndrome and Inflammatory Arthritis at Diagnosis in Hodgkin Lymphoma
  • DOI:
    10.1016/j.clml.2012.09.006
  • 发表时间:
    2013-02-01
  • 期刊:
  • 影响因子:
  • 作者:
    Daniel B. Aruch;Martha P. Mims
  • 通讯作者:
    Martha P. Mims
Clinical Outcomes of Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma in a County Hospital System
  • DOI:
    10.1182/blood-2023-173927
  • 发表时间:
    2023-11-02
  • 期刊:
  • 影响因子:
  • 作者:
    Jun Yang Jiang;Chijioke Nze;Danielle Guffey;Rockbum Kim;Abiodun O. Ouyomi;Omar Rosales;Raka Bandyo;Akiva Diamond;Gustavo A. Rivero;Courtney Nicole Miller-Chism;Mark M. Udden;Martha P. Mims;Christopher R. Flowers;Ang Li;Purnima Sravanti Teegavarapu
  • 通讯作者:
    Purnima Sravanti Teegavarapu
Disparities Among Adolescent and Young Adult Patients with Acute Lymphoblastic Leukemia
  • DOI:
    10.1182/blood-2023-190913
  • 发表时间:
    2023-11-02
  • 期刊:
  • 影响因子:
  • 作者:
    Elyse Lopez;Deepa Dongarwar;Martha P. Mims;Sara Taveras Alam
  • 通讯作者:
    Sara Taveras Alam
Real-World Validation of the European Leukemia Network 2022 Risk Stratification in Acute Myelogenous Leukemia
  • DOI:
    10.1182/blood-2023-189309
  • 发表时间:
    2023-11-02
  • 期刊:
  • 影响因子:
  • 作者:
    Sarah Elizabeth Mudra;Paul Sackstein;Lacey Scott Williams;Garrett Diltz;Rachel Zemel;Ashwin Kumar;Purnima Sravanti Teegavarapu;Martha P. Mims;Catherine Lai;Kimberley Doucette;Gustavo A. Rivero
  • 通讯作者:
    Gustavo A. Rivero
Clinical outcomes of patients with newly diagnosed large B-cell lymphoma in a safety-net hospital system
  • DOI:
    10.1016/j.bneo.2024.100020
  • 发表时间:
    2024-09-01
  • 期刊:
  • 影响因子:
  • 作者:
    Jun Y. Jiang;Chijioke Nze;Danielle Guffey;Rockbum Kim;Abiodun O. Oluyomi;Omar Rosales;Raka Bandyo;Courtney N. Miller-Chism;Mark M. Udden;Martha P. Mims;Hilary Ma;Gustavo A. Rivero;Akiva Diamond;Purnima S. Teegavarapu;Ang Li;Christopher R. Flowers
  • 通讯作者:
    Christopher R. Flowers

Martha P. Mims的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Martha P. Mims', 18)}}的其他基金

CLINICAL TRIALS SUPPORT UNIT
临床试验支持单位
  • 批准号:
    8181015
  • 财政年份:
    2010
  • 资助金额:
    $ 16.19万
  • 项目类别:
Clinical, Protocol and Data Management
临床、方案和数据管理
  • 批准号:
    10674569
  • 财政年份:
    2007
  • 资助金额:
    $ 16.19万
  • 项目类别:
Clinical Trials Support Unit
临床试验支持单位
  • 批准号:
    7514693
  • 财政年份:
    2007
  • 资助金额:
    $ 16.19万
  • 项目类别:
Clinical, Protocol and Data Management
临床、方案和数据管理
  • 批准号:
    10439832
  • 财政年份:
    2007
  • 资助金额:
    $ 16.19万
  • 项目类别:
DMT1:Tissue specific expression & alternative splicing
DMT1:组织特异性表达
  • 批准号:
    6858234
  • 财政年份:
    2005
  • 资助金额:
    $ 16.19万
  • 项目类别:
DMT1:Tissue specific expression & alternative splicing
DMT1:组织特异性表达
  • 批准号:
    7031607
  • 财政年份:
    2005
  • 资助金额:
    $ 16.19万
  • 项目类别:
DYNAMICS OF APOE BINDING TO LIPOPROTEINS AND RECEPTORS
APOE 与脂蛋白和受体结合的动力学
  • 批准号:
    2223250
  • 财政年份:
    1993
  • 资助金额:
    $ 16.19万
  • 项目类别:
DYNAMICS OF APOE BINDING TO LIPOPROTEINS AND RECEPTORS
APOE 与脂蛋白和受体结合的动力学
  • 批准号:
    2392677
  • 财政年份:
    1993
  • 资助金额:
    $ 16.19万
  • 项目类别:
DYNAMICS OF APOE BINDING TO LIPOPROTEINS AND RECEPTORS
APOE 与脂蛋白和受体结合的动力学
  • 批准号:
    2223251
  • 财政年份:
    1993
  • 资助金额:
    $ 16.19万
  • 项目类别:
DYNAMICS OF APOE BINDING TO LIPOPROTEINS AND RECEPTORS
APOE 与脂蛋白和受体结合的动力学
  • 批准号:
    2223252
  • 财政年份:
    1993
  • 资助金额:
    $ 16.19万
  • 项目类别:

相似国自然基金

肝脏脂蛋白脂肪酶LPL的关键性转录抑制因子的鉴定及其对血脂稳态的调节作用
  • 批准号:
    31871196
  • 批准年份:
    2018
  • 资助金额:
    60.0 万元
  • 项目类别:
    面上项目
氢分子改善代谢综合征所致高密度脂蛋白功能损害的分子机制
  • 批准号:
    81770855
  • 批准年份:
    2017
  • 资助金额:
    56.0 万元
  • 项目类别:
    面上项目
进食活化ANGPTL3的分子机制及其在血脂异常发生发展中的作用机理研究
  • 批准号:
    31771304
  • 批准年份:
    2017
  • 资助金额:
    61.0 万元
  • 项目类别:
    面上项目
姜黄素烟酸酯调节IDOL泛素化降低血浆LDL-C的作用机制
  • 批准号:
    81600291
  • 批准年份:
    2016
  • 资助金额:
    17.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Extra-hepatic postprandial metabolism of dietary fructose
膳食果糖的肝外餐后代谢
  • 批准号:
    10614587
  • 财政年份:
    2022
  • 资助金额:
    $ 16.19万
  • 项目类别:
Extra-hepatic postprandial metabolism of dietary fructose
膳食果糖的肝外餐后代谢
  • 批准号:
    10418420
  • 财政年份:
    2022
  • 资助金额:
    $ 16.19万
  • 项目类别:
Effect of sphingomyelin biosynthesis on atherosclerosis
鞘磷脂生物合成对动脉粥样硬化的影响
  • 批准号:
    10320422
  • 财政年份:
    2020
  • 资助金额:
    $ 16.19万
  • 项目类别:
Molecular mechanisms underlying the genetic association between PPP1R3B and hepatic steatosis
PPP1R3B与肝脂肪变性遗传关联的分子机制
  • 批准号:
    10224175
  • 财政年份:
    2018
  • 资助金额:
    $ 16.19万
  • 项目类别:
Functional studies of KLF14, a putative master regulator of metabolism
KLF14(假定的代谢主调节因子)的功能研究
  • 批准号:
    8886598
  • 财政年份:
    2015
  • 资助金额:
    $ 16.19万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了